Title: 2015 ACVIM Forum Research Abstract Program Document date: 2015_5_27
ID: 3pnuj5ru_771
Snippet: Pilot data showed maropitant reduced clinical signs based on client surveys (mild improvement: 3/7, marked improvement: 4/7) and significantly decreased VAS scores (P = 0.002). No difference in BALF % neutrophils or % eosinophils were noted with treatment (P = 0.165, P = 0.710). Subjective clinical improvement could reflect antitussive properties of maropitant or a placebo effect. Preliminary results suggest a lack of reduction of airway inflamma.....
Document: Pilot data showed maropitant reduced clinical signs based on client surveys (mild improvement: 3/7, marked improvement: 4/7) and significantly decreased VAS scores (P = 0.002). No difference in BALF % neutrophils or % eosinophils were noted with treatment (P = 0.165, P = 0.710). Subjective clinical improvement could reflect antitussive properties of maropitant or a placebo effect. Preliminary results suggest a lack of reduction of airway inflammation, making maropitant unsuitable for treatment of canine CB. Stent placement has been shown to decrease clinical signs and improve quality of life in dogs with tracheal collapse when medical management fails. Stent fractures occasionally occur which complicates post-operative care, raises cost, and decreases operator and owner satisfaction. Coughing likely plays a causative role but variations in clinical signs, disease severity, and operator preferences makes comparing stents based on clinical outcomes problematic. The aim of this study was to evaluate the fatigue properties of two types of tracheal stents in a controlled environment that simulated chronic coughing.
Search related documents:
Co phrase search for related documents- airway inflammation and causative role: 1, 2
- airway inflammation and clinical improvement: 1, 2, 3
- airway inflammation and clinical outcome: 1, 2, 3, 4, 5
- airway inflammation and disease severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- airway inflammation and eosinophil BALF neutrophil: 1
- airway inflammation reduction and BALF neutrophil: 1
- airway inflammation reduction and eosinophil BALF neutrophil: 1
- BALF neutrophil and disease severity: 1, 2
- BALF neutrophil and eosinophil BALF neutrophil: 1, 2
- causative role and disease severity: 1, 2
- client survey and clinical improvement: 1
- clinical improvement and disease severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical outcome and disease severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical sign and disease severity: 1, 2, 3, 4, 5, 6
- control environment and disease severity: 1
Co phrase search for related documents, hyperlinks ordered by date